Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826894 | 1.00 | ALDH1A1 (0.62) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL22955043 | 0.83 | ALDH1A1 (0.56) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL22955597 | 0.83 | ALDH1A1 (0.56) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL1829917 | 0.82 | ALDH1A1 (0.54) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL1727452 | 0.77 | ALDH1A1 (0.49) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL21222695 | 0.77 | ALDH1A1 (0.38) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL29365374 | 0.77 | ALDH1A1 (1.00) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL378958 | 0.77 | ALDH1A1 (1.00) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL27590599 | 0.77 | ALDH1A1 (0.55) | ALDH1A1IMPDH2KDM4EPOLBTDP1 | |
| SCHEMBL788705 | 0.76 | MEN1 (0.45) | ALDH1A1IMPDH2KDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023089225-A1 | EXTRACTION OF PEPTIDES AND GLUCOSINOLATES FROM PLANT MATERIAL OF THE BRASSICA GENUS AND USE THEREOF IN COSMETIC APPLICATIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2023-05-25 | — | — | WO | claimed |
| WO-2007126889-A1 | PREPARATION OF TEGASEROD ACETATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-08 | — | — | WO | claimed |
| WO-2007084761-A1 | MALEATE SALT OF TEGASEROD AND CRYSTALLINE FORMS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-07-26 | — | — | WO | claimed |
| EP-4006014-B1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LTD (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023089225-A1 | EXTRACTION OF PEPTIDES AND GLUCOSINOLATES FROM PLANT MATERIAL OF THE BRASSICA GENUS AND USE THEREOF IN COSMETIC APPLICATIONS | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2023-05-25 | — | — | WO | disclosed |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED (CN) | 2022-12-20 | — | — | US | disclosed |
| EP-4006014-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | Medshine Discovery Inc. (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021018017-A1 | PYRIMIDINE COMPOUND ACTING ON EGFR AND ERBB2 | 南京明德新药研发有限公司 | 2021-02-04 | — | — | WO | disclosed |
| US-9458200-B2 | Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles | GOTTFRIED WILHELM LEIBNIZ UNIVERSITÄT HANNOVER (DE) | 2016-10-04 | — | — | US | disclosed |
| EP-2605658-A1 | SPIROXAZOLIDINONE COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2303916-B1 | METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES | HELMHOLTZ INFEKTIONSFORSCHUNG (DE) | 2012-05-09 | — | — | EP | disclosed |
| US-20110311564-A1 | Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles | GOTTFRIED WILHELM LEIBNIZ UNIVERSITAT HANNOVER (DE) | 2011-12-22 | — | — | US | disclosed |
| EP-2303916-A1 | METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2010030727-A1 | 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010006682-A1 | METHOD FOR PRODUCING INTERMEDIATES FOR THE PRODUCTION OF NOVEL MACROCYCLES THAT ARE INHIBITORS OF THE PROTEASOMIC DEGRADATION OF P27, SUCH AS ARGYRIN AND DERIVATIVES THEREOF, AND USES OF SAID MACROCYCLES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-01-21 | — | — | WO | disclosed |
| EP-2138507-A1 | Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-6656963-B2 | Inhibits tumor cell growth | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-12-02 | — | — | US | disclosed |
| US-20030087946-A1 | Indole-3-carbinol (I3C) derivatives and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-08 | — | — | US | disclosed |
| US-6369095-B1 | ANTITUMOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-04-09 | — | — | US | disclosed |
| US-6150395-A | CYCLIN DEPENDENT KINASE (CDK) INHIBITORS INHIBIT THE GROWTH OF ESTROGEN-DEPENDENT OR INDEPENDENT BREAST CANCER CELLS AND OTHER TYPES OF CANCER CELLS THAT REVEAL INDUCED CDK6; ANTIESTROGENS; ANTITUMOR AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087946-A1 | Indole-3-carbinol (I3C) derivatives and methods | CDK6, CDK3, CDKL3 | ALDH1A1 3650/4885IMPDH2 860/4885KDM4E 1015/4885 |
| US-11530196-B2 | Pyrimidine compound acting on EGFR and ERBB2 | ERBB2, ERBB3, EGFR | ALDH1A1 3162/4885IMPDH2 611/4885KDM4E 4188/4885 |
| US-20110311564-A1 | Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles | SKP2, CDKN1A, PSMC1 | ALDH1A1 3888/4885IMPDH2 1500/4885KDM4E 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.